Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2017, Article ID 8518929, 8 pages
https://doi.org/10.1155/2017/8518929
Clinical Study

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson’s Disease

1Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea
2Department of Neurology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea
3Department of Neurology, Ulsan University Hospital, Ulsan, Republic of Korea
4Department of Neurology and Movement Disorder Center, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea

Correspondence should be addressed to Beomseok Jeon; rk.ca.uns@niarb

Received 10 August 2016; Revised 14 December 2016; Accepted 15 January 2017; Published 7 February 2017

Academic Editor: Antonio Pisani

Copyright © 2017 Ji Young Yun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. G. Goetz, W. Poewe, O. Rascol, and C. Sampaio, “Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004,” Movement Disorders, vol. 20, no. 5, pp. 523–539, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Pahwa, S. A. Factor, K. E. Lyons et al., “Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology,” Neurology, vol. 66, no. 7, pp. 983–995, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. C. W. Olanow, A. H. V. Schapira, and O. Rascol, “Continuous dopamine-receptor stimulation in early Parkinson's disease,” Trends in Neurosciences, vol. 23, no. 10, pp. S117–S126, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. J. A. Obeso, M. C. Rodriguez-Oroz, P. Chana et al., “The evolution and origin of motor complications in Parkinson's disease,” Neurology, vol. 55, no. 11, supplement 4, pp. S13–S23, 2000. View at Google Scholar · View at Scopus
  5. D. Grosset, A. Antonini, M. Canesi et al., “Adherence to Antiparkinson medication in a Multicenter European study,” Movement Disorders, vol. 24, no. 6, pp. 826–832, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Pahwa, M. A. Stacy, S. A. Factor et al., “Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease,” Neurology, vol. 68, no. 14, pp. 1108–1115, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Poewe, O. Rascol, P. Barone et al., “Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial,” Neurology, vol. 77, no. 8, pp. 759–766, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. A. H. V. Schapira, P. Barone, R. A. Hauser et al., “Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial,” Neurology, vol. 77, no. 8, pp. 767–774, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. R. A. Hauser, A. H. V. Schapira, O. Rascol et al., “Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease,” Movement Disorders, vol. 25, no. 15, pp. 2542–2549, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Antonini and D. Calandrella, “Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients,” Neuropsychiatric Disease and Treatment, vol. 7, no. 1, pp. 297–302, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Y. Yun, H.-J. Kim, J.-Y. Lee et al., “Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson's disease,” BMC Neurology, vol. 13, article 113, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. A. J. Hughes, S. E. Daniel, L. Kilford, and A. J. Lees, “Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases,” Journal of Neurology Neurosurgery and Psychiatry, vol. 55, no. 3, pp. 181–184, 1992. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Martinez-Martin, A. Gil-Nagel, L. M. Gracia et al., “Unified Parkinson's disease rating scale characteristics and structure,” Movement Disorders, vol. 9, no. 1, pp. 76–83, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. C. G. Goetz, W. Poewe, O. Rascol et al., “Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations,” Movement Disorders, vol. 19, no. 9, pp. 1020–1028, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. J. S. Baik, J. Y. Kim, and J. H. Park, “Parkinson's disease sleep scale in Korea,” Journal of the Korean Neurological Association, vol. 23, no. 1, pp. 41–48, 2005. View at Google Scholar
  16. K. R. Chaudhuri and P. Martinez-Martin, “Clinical assessment of nocturnal disability in Parkinson's disease: the Parkinson's Disease Sleep Scale,” Neurology, vol. 63, no. 8, supplement 3, pp. S17–S20, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. M. W. Johns, “A new method for measuring daytime sleepiness: the epworth sleepiness scale,” Sleep, vol. 14, no. 6, pp. 540–545, 1991. View at Google Scholar · View at Scopus
  18. Y. W. Cho, J. H. Lee, H. K. Son, S. H. Lee, C. Shin, and M. W. Johns, “The reliability and validity of the Korean version of the Epworth sleepiness scale,” Sleep and Breathing, vol. 15, no. 3, pp. 377–384, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. A. H. V. Schapira, P. Barone, R. A. Hauser et al., “Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease,” European Journal of Neurology, vol. 20, no. 1, pp. 50–56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. R. A. Hauser, L. Gauger, W. M. Anderson, and T. A. Zesiewicz, “Pramipexole-induced somnolence and episodes of daytime sleep,” Movement Disorders, vol. 15, no. 4, pp. 658–663, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Paus, H. M. Brecht, J. Köster, G. Seeger, T. Klockgether, and U. Wüllner, “Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease,” Movement Disorders, vol. 18, no. 6, pp. 659–667, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Ryan, J. T. Slevin, and A. Wells, “Non-ergot dopamine agonist-induced sleep attacks,” Pharmacotherapy, vol. 20, no. 6, pp. 724–726, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. D. J. Tompson and D. Vearer, “Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease,” Clinical Therapeutics, vol. 29, no. 12, pp. 2654–2666, 2007. View at Publisher · View at Google Scholar · View at Scopus